BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Centonze D, Rocca MA, Gasperini C, Kappos L, Hartung HP, Magyari M, Oreja-Guevara C, Trojano M, Wiendl H, Filippi M. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol 2021. [PMID: 33844056 DOI: 10.1007/s00415-021-10545-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Capone F, Lucchini M, Ferraro E, Bianco A, Rossi M, Cicia A, Cortese A, Cruciani A, De Arcangelis V, De Giglio L, Motolese F, Sancetta B, Mirabella M, Di Lazzaro V. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics 2021. [PMID: 34859382 DOI: 10.1007/s13311-021-01165-9] [Reference Citation Analysis]
2 Winkelmann A, Loebermann M, Barnett M, Hartung HP, Zettl UK. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol 2022. [PMID: 35388213 DOI: 10.1038/s41582-022-00646-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Golshani M, Hrdý J. Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination. Vaccines 2022;10:279. [DOI: 10.3390/vaccines10020279] [Reference Citation Analysis]
4 Maniscalco GT, Ferrara AL, Liotti A, Manzo V, Battista MED, Salvatore S, Graziano D, Viola A, Amato G, Moreggia O, Cesare DDG, Alfieri G, Iorio WD, Rocca GD, Andreone V, De Rosa V. Long term persistence of SARS-CoV-2 humoral response in Multiple Sclerosis subjects. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103800] [Reference Citation Analysis]
5 Wang Z, Liu H, Li Y, Luo X, Yang N, Lv M, Zhou Q, Li Q, Wang L, Zhao J, Liu Y, Su R, Wu S, Liu X, Zhao S, Shi Q, Estill J, Liu X, Zhang W, Chen Y. COVID-19 vaccine guidelines was numerous in quantity but many lack transparent reporting of methodological practices. J Clin Epidemiol 2021:S0895-4356(21)00419-4. [PMID: 34920115 DOI: 10.1016/j.jclinepi.2021.12.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Toscano S, Chisari CG, Patti F. Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. Neurol Ther 2021;10:627-49. [PMID: 34625925 DOI: 10.1007/s40120-021-00288-7] [Reference Citation Analysis]
7 Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C. Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies. J Neurol 2022. [PMID: 34984514 DOI: 10.1007/s00415-021-10951-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Paybast S, Emami A, Baghalha F, Naser Moghadasi A. Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know? Mult Scler Relat Disord 2022;65:103960. [PMID: 35763914 DOI: 10.1016/j.msard.2022.103960] [Reference Citation Analysis]
9 Grothe C, Steffen F, Bittner S. Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets. J Cent Nerv Syst Dis 2021;13:11795735211060118. [PMID: 34880703 DOI: 10.1177/11795735211060118] [Reference Citation Analysis]
10 Pugliatti M, Berger T, Hartung HP, Oreja-Guevara C, Bar-Or A. Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations. Curr Opin Neurol 2022;35:319-27. [PMID: 35674075 DOI: 10.1097/WCO.0000000000001066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Khayat-Khoei M, Bhattacharyya S, Katz J, Harrison D, Tauhid S, Bruso P, Houtchens MK, Edwards KR, Bakshi R. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol 2021. [PMID: 34480607 DOI: 10.1007/s00415-021-10780-7] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Maniscalco GT, Manzo V, Ferrara AL, Perrella A, Di Battista M, Salvatore S, Graziano D, Viola A, Amato G, Moreggia O, Di Giulio Cesare D, Barbato S, Servillo G, Longo K, Di Giovanni M, Scarpati B, Muggianu SM, Longo G, Russo G, Andreone V, De Rosa V. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. Multiple Sclerosis and Related Disorders 2022;58:103455. [DOI: 10.1016/j.msard.2021.103455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Maniscalco GT, Manzo V, Di Battista ME, Salvatore S, Moreggia O, Scavone C, Capuano A. Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report. Front Neurol 2021;12:721502. [PMID: 34447349 DOI: 10.3389/fneur.2021.721502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
14 Freedman MS, Jack D, Murgašová Z, Todorović M, Seitzinger A. Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis. Mult Scler Relat Disord 2021;56:103283. [PMID: 34619487 DOI: 10.1016/j.msard.2021.103283] [Reference Citation Analysis]
15 Tornatore C, Wiendl H, Lublin AL, Geertsen SS, Chavin J, Truffinet P, Bar-or A. Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide. Front Neurol 2022;13:828616. [DOI: 10.3389/fneur.2022.828616] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol 2021. [PMID: 34382120 DOI: 10.1007/s00415-021-10744-x] [Reference Citation Analysis]
17 Bellucci G, Rinaldi V, Buscarinu MC, Reniè R, Bigi R, Pellicciari G, Morena E, Romano C, Marrone A, Mechelli R, Salvetti M, Ristori G. Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started? Front Immunol 2021;12:755333. [PMID: 34646278 DOI: 10.3389/fimmu.2021.755333] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C. Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies. J Neurol 2021. [PMID: 34533590 DOI: 10.1007/s00415-021-10803-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Woopen C, Schleußner K, Akgün K, Ziemssen T. Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Front Immunol 2021;12:701752. [PMID: 34234787 DOI: 10.3389/fimmu.2021.701752] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Jakimovski D, Weinstock-Guttman B. Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient. Acta Neurol Belg 2022;122:565-6. [PMID: 34529258 DOI: 10.1007/s13760-021-01799-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]